Tuesday 1 March 2011
Tremelimumab (anti-CTLA4) associated colitis. Intra-epithelial & lamina propria neutrophilia. Lymphoplasmacytosis of lamina propria
Tremelimumab is a fully human IgG2 monoclonal antibody produced by Pfizer. Tremelimumab binds to the protein CTLA-4 , which is expressed on the surface of activated T lymphocytes.
Tremelimumab blocks the binding of the antigen-presenting cell ligands B7.1 and B7.2 to CTLA-4, resulting in inhibition of B7-CTLA-4-mediated downregulation of T-cell activation.
anti-CTLA-4 / CTLA-4 blockade